Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says
By Patrick Wingrove (Reuters) – Eli Lilly on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials. U.S.-based Lilly and Danish rival Novo Nordisk are in a race to get their obesity drugs approved to treat other ailments. Novo’s…